JP2000504327A - 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方 - Google Patents
高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方Info
- Publication number
- JP2000504327A JP2000504327A JP9526917A JP52691797A JP2000504327A JP 2000504327 A JP2000504327 A JP 2000504327A JP 9526917 A JP9526917 A JP 9526917A JP 52691797 A JP52691797 A JP 52691797A JP 2000504327 A JP2000504327 A JP 2000504327A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- factor
- concentration
- arginine
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100022641 Coagulation factor IX Human genes 0.000 title claims abstract description 122
- 108010076282 Factor IX Proteins 0.000 title claims abstract description 121
- 229960004222 factor ix Drugs 0.000 title claims abstract description 118
- 239000007788 liquid Substances 0.000 title abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 106
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 60
- 229930006000 Sucrose Natural products 0.000 claims description 46
- 239000005720 sucrose Substances 0.000 claims description 45
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 44
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 30
- 239000004471 Glycine Substances 0.000 claims description 30
- 229930195725 Mannitol Natural products 0.000 claims description 30
- 239000000594 mannitol Substances 0.000 claims description 30
- 235000010355 mannitol Nutrition 0.000 claims description 30
- 239000004475 Arginine Substances 0.000 claims description 29
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 20
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 16
- 239000002577 cryoprotective agent Substances 0.000 claims description 14
- 229920000136 polysorbate Polymers 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 239000006172 buffering agent Substances 0.000 claims description 12
- 229950008882 polysorbate Drugs 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005695 Ammonium acetate Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 229940043376 ammonium acetate Drugs 0.000 claims description 4
- 235000019257 ammonium acetate Nutrition 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 45
- 238000003860 storage Methods 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 56
- 230000000694 effects Effects 0.000 description 41
- 229960004793 sucrose Drugs 0.000 description 32
- 238000007920 subcutaneous administration Methods 0.000 description 20
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 16
- 229960003589 arginine hydrochloride Drugs 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000035602 clotting Effects 0.000 description 11
- 239000001509 sodium citrate Substances 0.000 description 11
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229960003121 arginine Drugs 0.000 description 9
- 229910001424 calcium ion Inorganic materials 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940126534 drug product Drugs 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- -1 Cextrose Polymers 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002357 osmotic agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- JTPJSRBSERJPKF-ODZAUARKSA-N 2-aminoacetic acid;(z)-but-2-enedioic acid Chemical compound NCC(O)=O.OC(=O)\C=C/C(O)=O JTPJSRBSERJPKF-ODZAUARKSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 102000000119 Beta-lactoglobulin Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VNUJRYVVHNOBFN-SQDRRJMKSA-N C(C)(=O)[O-].C(\C=C/C(=O)[O-])(=O)[O-].[NH4+].[NH4+].[NH4+] Chemical compound C(C)(=O)[O-].C(\C=C/C(=O)[O-])(=O)[O-].[NH4+].[NH4+].[NH4+] VNUJRYVVHNOBFN-SQDRRJMKSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101100001675 Emericella variicolor andJ gene Proteins 0.000 description 1
- 206010016077 Factor IX deficiency Diseases 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108010056902 Mononine Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HEAFLBOWLRRIHV-UHFFFAOYSA-N [Na].[P] Chemical compound [Na].[P] HEAFLBOWLRRIHV-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000011094 buffer selection Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940036474 factor IX injection Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 229960000027 human factor ix Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 229940090053 mononine Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108010025221 plasma protein Z Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/591,332 US5770700A (en) | 1996-01-25 | 1996-01-25 | Liquid factor IX formulations |
| US08/591,332 | 1996-01-25 | ||
| PCT/US1997/000747 WO1997026909A1 (en) | 1996-01-25 | 1997-01-09 | Highly concentrated, lyophilized, and liquid factor ix formulations |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006141684A Division JP2006257099A (ja) | 1996-01-25 | 2006-05-22 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2007180835A Division JP4879104B2 (ja) | 1996-01-25 | 2007-07-10 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000504327A true JP2000504327A (ja) | 2000-04-11 |
| JP2000504327A5 JP2000504327A5 (enExample) | 2004-10-28 |
Family
ID=24366077
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9526917A Withdrawn JP2000504327A (ja) | 1996-01-25 | 1997-01-09 | 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方 |
| JP2006141684A Pending JP2006257099A (ja) | 1996-01-25 | 2006-05-22 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2007180835A Expired - Lifetime JP4879104B2 (ja) | 1996-01-25 | 2007-07-10 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2010106673A Withdrawn JP2010189433A (ja) | 1996-01-25 | 2010-05-06 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006141684A Pending JP2006257099A (ja) | 1996-01-25 | 2006-05-22 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2007180835A Expired - Lifetime JP4879104B2 (ja) | 1996-01-25 | 2007-07-10 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2010106673A Withdrawn JP2010189433A (ja) | 1996-01-25 | 2010-05-06 | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5770700A (enExample) |
| EP (1) | EP0876155B1 (enExample) |
| JP (4) | JP2000504327A (enExample) |
| AT (1) | ATE270557T1 (enExample) |
| AU (1) | AU726498B2 (enExample) |
| CA (1) | CA2241319A1 (enExample) |
| DE (1) | DE69729786T2 (enExample) |
| WO (1) | WO1997026909A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005516998A (ja) * | 2002-02-06 | 2005-06-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 免疫サイトカイン含有凍結乾燥製剤 |
| JP2007262090A (ja) * | 1996-01-25 | 2007-10-11 | Genetics Inst Llc | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2009161538A (ja) * | 2001-03-05 | 2009-07-23 | Bayer Schering Pharma Ag | 顆粒球マクロファージ・コロニー刺激因子の安定性のある水溶液 |
| JP2010530846A (ja) * | 2007-06-01 | 2010-09-16 | アコロジックス インコーポレイティッド | 高温で安定なペプチド製剤 |
| JP2012500041A (ja) * | 2008-08-15 | 2012-01-05 | ヘムコン メディカル テクノロジーズ， インコーポレイテッド | 凍結乾燥物質、例えば凍結乾燥血漿を製造、貯蔵、および投与するための装置およびシステム |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US20080050367A1 (en) * | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| JP3581660B2 (ja) | 1999-04-30 | 2004-10-27 | ラ ホヤ インスティチュート フォー アラジー アンド イムノロジー | 潜伏ウイルスの再活性化を予防しウイルスの複製を制御するための方法 |
| US7112576B1 (en) | 1999-12-10 | 2006-09-26 | Regents Of The University Of Minnesota | Compositions and methods for cryopreservation of peripheral blood lymphocytes |
| IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| WO2002039951A2 (en) * | 2000-11-15 | 2002-05-23 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| AU2002351755A1 (en) * | 2001-12-21 | 2003-07-15 | Novo Nordisk A/S | Liquid composition of modified factor vii polypeptides |
| KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
| ES2325653T3 (es) * | 2001-12-21 | 2009-09-11 | Novo Nordisk Health Care Ag | Composicion liquida de polipeptidos del factor vii. |
| MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| BRPI0311959B8 (pt) | 2002-06-21 | 2021-05-25 | Novo Nordisk Healthcare Ag | composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP1594969B1 (en) * | 2003-02-01 | 2015-05-20 | Janssen Sciences Ireland UC | Active immunization to generate antibodies to soluble a-beta |
| EP1605968A2 (en) * | 2003-03-18 | 2005-12-21 | Novo Nordisk Health Care AG | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| WO2004091658A1 (en) * | 2003-04-04 | 2004-10-28 | Genentech, Inc. | High concentration antibody and protein formulations |
| WO2004103398A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
| TWI306458B (en) * | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| ES2382157T3 (es) * | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
| WO2005002615A1 (en) * | 2003-07-01 | 2005-01-13 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
| KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| KR20130026498A (ko) * | 2003-12-19 | 2013-03-13 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물 |
| DE602005024955D1 (de) | 2004-03-19 | 2011-01-05 | Baxter Healthcare Sa | Faktor ixa zur behandlung von blutungsstörungen |
| MXPA06015234A (es) * | 2004-06-30 | 2007-11-22 | Nektar Therapeutics Al Corp | Conjugados de fraccion polimero-factor ix. |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| CA2589017A1 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Amyloid beta antibodies for use in improving cognition |
| AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
| WO2006066049A2 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| TW200638943A (en) * | 2005-01-28 | 2006-11-16 | Wyeth Corp | Stabilized liquid polypeptide formulations |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| ATE490343T1 (de) * | 2005-06-30 | 2010-12-15 | Ge Healthcare Bio Sciences | Nachweisverfahren für die genexpression |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| LT2944306T (lt) | 2006-06-16 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Vfgf antagonisto kompozicijos, tinkamos įvedimui intravitrealiniu būdu |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| AU2008245821B2 (en) | 2007-04-26 | 2013-07-04 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
| US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
| SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
| WO2009020744A1 (en) | 2007-08-07 | 2009-02-12 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations comprising gdf-5 in aqueous acidic solution |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| CA2720845A1 (en) * | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| TW201039854A (en) | 2009-03-06 | 2010-11-16 | Genentech Inc | Antibody formulation |
| AU2011219612A1 (en) | 2010-02-24 | 2012-09-06 | Arecor Limited | Stable compositions of Factor IX |
| LT3345615T (lt) | 2010-03-01 | 2020-02-10 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| SG10201913874TA (en) | 2013-03-15 | 2020-03-30 | Biogen Ma Inc | Factor ix polypeptide formulations |
| US9658225B2 (en) | 2013-03-15 | 2017-05-23 | Hycor Biomedical, Llc | Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases |
| WO2015148444A1 (en) * | 2014-03-24 | 2015-10-01 | Biogen Ma Inc. | Lyophilized factor ix formulations |
| AU2016364817B2 (en) | 2015-12-03 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| CN111295094A (zh) | 2017-10-09 | 2020-06-16 | 泰尔茂比司特生物技术有限公司 | 冻干容器及使用冻干容器的方法 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2020242552A1 (en) | 2019-03-14 | 2020-12-03 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3045153A1 (de) * | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
| US4470968A (en) * | 1983-01-13 | 1984-09-11 | Miles Laboratories, Inc. | Pasteurized therapeutically active blood coagulation factor concentrates |
| US4540573A (en) * | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| IT1171737B (it) * | 1983-10-10 | 1987-06-10 | Vamatex Spa | Gancio per la guida di nastri portapinze all'interno del passo di telai di tessitura e complesso di guida con esso realizzabile |
| US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| US4952675A (en) * | 1985-02-01 | 1990-08-28 | New York University | Method for purifying antihemophilic factor |
| EP0218713B1 (en) * | 1985-04-22 | 1992-03-25 | Genetics Institute, Inc. | High yield production of active factor ix |
| JP2577744B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
| DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
| JP2708749B2 (ja) * | 1987-08-10 | 1998-02-04 | エーザイ株式会社 | 修飾型ｔＰＡ含有注射用組成物 |
| EP0317376B2 (fr) * | 1987-10-23 | 1996-04-03 | Centre Regional De Transfusion Sanguine De Lille | Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques |
| DE3828009A1 (de) * | 1988-08-18 | 1990-02-22 | Wolfgang D Zapp | Rahmen aus strangprofilen |
| JP2715104B2 (ja) * | 1988-08-18 | 1998-02-18 | 株式会社ミドリ十字 | トロンビン乾燥製剤 |
| DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| JP2722143B2 (ja) * | 1991-09-03 | 1998-03-04 | 株式会社ミドリ十字 | トリプシンインヒビター含有凍結乾燥製剤 |
| JPH05331071A (ja) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 |
| US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| IT1254359B (it) * | 1992-05-11 | 1995-09-14 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti il-6 |
| DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度ｔｃｆ製剤 |
| JP3007785B2 (ja) * | 1993-03-16 | 2000-02-07 | 旭化成工業株式会社 | トロンボモジュリン組成物およびその変性防止方法 |
| JP3537440B2 (ja) * | 1993-12-17 | 2004-06-14 | 持田製薬株式会社 | 可溶性トロンボモジュリンを長期保存安定化させる方法 |
| IL113010A (en) * | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| US6372716B1 (en) * | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
-
1996
- 1996-01-25 US US08/591,332 patent/US5770700A/en not_active Expired - Lifetime
-
1997
- 1997-01-09 AU AU17500/97A patent/AU726498B2/en not_active Ceased
- 1997-01-09 DE DE69729786T patent/DE69729786T2/de not_active Expired - Lifetime
- 1997-01-09 EP EP97904797A patent/EP0876155B1/en not_active Expired - Lifetime
- 1997-01-09 CA CA002241319A patent/CA2241319A1/en not_active Abandoned
- 1997-01-09 AT AT97904797T patent/ATE270557T1/de not_active IP Right Cessation
- 1997-01-09 WO PCT/US1997/000747 patent/WO1997026909A1/en not_active Ceased
- 1997-01-09 JP JP9526917A patent/JP2000504327A/ja not_active Withdrawn
-
2006
- 2006-05-22 JP JP2006141684A patent/JP2006257099A/ja active Pending
-
2007
- 2007-07-10 JP JP2007180835A patent/JP4879104B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-06 JP JP2010106673A patent/JP2010189433A/ja not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007262090A (ja) * | 1996-01-25 | 2007-10-11 | Genetics Inst Llc | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 |
| JP2009161538A (ja) * | 2001-03-05 | 2009-07-23 | Bayer Schering Pharma Ag | 顆粒球マクロファージ・コロニー刺激因子の安定性のある水溶液 |
| JP2005516998A (ja) * | 2002-02-06 | 2005-06-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 免疫サイトカイン含有凍結乾燥製剤 |
| JP2010530846A (ja) * | 2007-06-01 | 2010-09-16 | アコロジックス インコーポレイティッド | 高温で安定なペプチド製剤 |
| JP2012500041A (ja) * | 2008-08-15 | 2012-01-05 | ヘムコン メディカル テクノロジーズ， インコーポレイテッド | 凍結乾燥物質、例えば凍結乾燥血漿を製造、貯蔵、および投与するための装置およびシステム |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1750097A (en) | 1997-08-20 |
| JP4879104B2 (ja) | 2012-02-22 |
| JP2007262090A (ja) | 2007-10-11 |
| CA2241319A1 (en) | 1997-07-31 |
| JP2010189433A (ja) | 2010-09-02 |
| US5770700A (en) | 1998-06-23 |
| WO1997026909A1 (en) | 1997-07-31 |
| ATE270557T1 (de) | 2004-07-15 |
| EP0876155A1 (en) | 1998-11-11 |
| JP2006257099A (ja) | 2006-09-28 |
| DE69729786T2 (de) | 2005-07-14 |
| AU726498B2 (en) | 2000-11-09 |
| DE69729786D1 (de) | 2004-08-12 |
| EP0876155B1 (en) | 2004-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4879104B2 (ja) | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 | |
| JP4789698B2 (ja) | 因子ｉｘ用処方 | |
| US20010031721A1 (en) | Highly concentrated, lyophilized, and liquid factor IX formulations | |
| KR101212025B1 (ko) | 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물 | |
| JP3905921B2 (ja) | 凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法 | |
| KR100491281B1 (ko) | 저당함량을가지는안정한알부민무함유재조합인자Vlll의제제 | |
| JP5253501B2 (ja) | 安定化トロンビン組成物 | |
| HK89495A (en) | Stabilized human protein preparations | |
| CZ293527B6 (cs) | Formulace s obsahem koagulačního faktoru VIII a způsob její přípravy | |
| EP2337580B1 (en) | Stabilized compositions for recombinantly produced factor viii | |
| KR20110086583A (ko) | 제8 인자 제형 | |
| US5747030A (en) | Pharmaceutical preparation containing plasminogen activators | |
| KR101710471B1 (ko) | 건조한 트랜스글루타미나제 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060217 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060522 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070313 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070718 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070611 |